Clinical trials

Statistically significant and clinically meaningful results seen in RemIND trial with complete responses achieved in 3 CIndU types1Remibrutinib,…

WASHINGTON (TNND) — Popular GLP-1 weight-loss medications have helped millions of people shed pounds, but new research from…

That protocol, according to the bill, would include a standardized fact-sheet handed to the customer describing ivermectin’s appropriate…

Compass Pathways soars as psilocybin depression treatment hits second Phase 3 trial goals Endpoints NewsCompass Pathways to Announce New…

Disc Medicine Inc FDA acknowledged that AURORA and BEACON provided sufficient evidence that bitopertin significantly lowers PPIX and…

BETHESDA, Md. (AP) — Melania Trump on Wednesday celebrated an early Valentine’s Day with children and young adults…

Dr. Peter Yu, physician-in-chief at the Hartford HealthCare Cancer Institute, clearly does not rest on his laurels. While…

A Spanish research team says it has developed a treatment that completely eliminated the most aggressive form of…

Jan 20 (Reuters) – Isomorphic Labs, which uses artificial intelligence for drug discovery, expects to have its first…

Pfizer’s (NYSE: PFE) shares have been southbound for the last three years. And unfortunately for the company, it…

NEW HAVEN, Conn., Dec. 24, 2025 /PRNewswire/ — Biohaven Ltd. (NYSE: BHVN) (“Biohaven”), a global clinical-stage biopharmaceutical company focused…

During the first three years of Augenstein’s lung cancer journey, he’s been happy to be able to share…

Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU)